

heat production obtained using a screening method described in (9); and
(14) A pharmaceutical composition containing a compound or its salt that promotes or inhibits UCP-2 promoter activity obtained using a screening method described in (8) or a screening kit described in (11).

BRIEF DESCRIPTION OF THE DRAWINGS

-SK 08/14/08

Figures 1A-1F show the base sequence of cDNA (SEQ ID NO:1) containing the human UCP-2 promoter region cloned in Example 1.

Figure 2 shows the luciferase activity measured in Example 2.

Figure 3 shows the luciferase activity measured in Example 3.

Figure 4 shows the structure of the UCP-2 promoter deficient-clones constructed in Example 4. The numbers in the Figure represent the base number starting from the transcription initiation site.

Figure 5 shows the promoter activity measured in Example 4.

BEST MODE OF EMBODIMENT OF THE INVENTION

A DNA containing the UCP-2 promoter region containing the regulatory sequence of this invention may be any DNA containing the regulatory sequence described below with UCP-2 promoter activity.

Specifically, a DNA of this invention may be any DNA containing the base sequence represented by position 1 to 2270 of SEQ ID NO: 1 or a part of said sequence.

A DNA of this invention may be genomic DNA, cDNA, and synthetic DNA derived from human and other mammalian cells (e.g. hepatocytes, splenocytes, neurocytes, glial cells, pancreatic β cells, bone